Another study based on ovarian cancer reported that apigenin decelerated ovarian cancer development via downregulating ER-mediated PI3K/AKT/mTOR expression, therefore demonstrating its applicability as a potentially effective therapeutic agent for ovarian cancer treatment [104]. Here, AKT1 is linked to ovarian cancer.